Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015636 | 1.00 | MMP12 (0.49) | MMP12PKMMAPTTP53PARP1 | |
| SCHEMBL24286262 | 0.93 | MMP12 (0.49) | MMP12PKMMAPTTP53PARP1 | |
| SCHEMBL2945700 | 0.86 | MMP12 (0.54) | MMP12PKMMAPTTP53PARP1 | |
| SCHEMBL2955843 | 0.86 | MMP12 (0.54) | MMP12PKMMAPTTP53PARP1 | |
| SCHEMBL5914785 | 0.80 | NR3C2 (0.51) | MMP12PKMMAPTTP53PARP1 | |
| SCHEMBL3342717 | 0.80 | MMP12 (0.49) | MMP12PKMMAPTTP53PARP1 | |
| SCHEMBL12067736 | 0.80 | ACLY (0.49) | MMP12PKMMAPTTP53PARP1 | |
| SCHEMBL3592276 | 0.80 | MMP12 (0.49) | MMP12PKMMAPTTP53PARP1 | |
| SCHEMBL1853066 | 0.80 | MMP12 (0.57) | MMP12PKMMAPTTP53PARP1 | |
| SCHEMBL30557601 | 0.80 | ACLY (0.49) | MMP12PKMMAPTTP53PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084815-A | Synthesis method of 7-bromo-6-chloro-3, 4-dihydro-2H-1, 4-benzoxazine | 南通大学 | 2024-05-28 | — | — | CN | claimed |
| CN-118084815-A | Synthesis method of 7-bromo-6-chloro-3, 4-dihydro-2H-1, 4-benzoxazine | 南通大学 | 2024-05-28 | — | — | CN | disclosed |
| US-11932633-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-110092782-B | Benzo-hexaazacyclo compound and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2022-10-21 | — | — | CN | disclosed |
| US-20210380570-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2021-12-09 | — | — | US | disclosed |
| CN-107646034-B | 3- (6-chloro-3-oxo-3, 4-dihydro- (2H) -1, 4-benzoxazin-4-yl) propionic acid derivatives or their use as KMO inhibitors | 爱丁堡大学理事会 | 2021-06-15 | — | — | CN | disclosed |
| EP-3790551-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10611756-B2 | Method of treating pancreatitis using 1,4-benzoxazine derivatives | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2020-04-07 | — | — | US | disclosed |
| US-10611756-B2 | Method of treating pancreatitis using 1,4-benzoxazine derivatives | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2020-04-07 | — | — | US | disclosed |
| WO-2019217307-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-11-14 | — | — | WO | disclosed |
| US-20190169178-A1 | METHODS | DR. FALK PHARMA GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169178-A1 | METHODS | DR. FALK PHARMA GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-10246447-B2 | 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-02 | — | — | US | disclosed |
| US-10246447-B2 | 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-02 | — | — | US | disclosed |
| US-20180170920-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | DR. FALK PHARMA GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180170920-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | DR. FALK PHARMA GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180170920-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | DR. FALK PHARMA GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| EP-3298009-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016188827-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016188827-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611756-B2 | Method of treating pancreatitis using 1,4-benzoxazine derivatives | AMY2A, KMO, KLK5 | MMP12 497/4885PKM 235/4885MAPT 4609/4885 |
| US-10246447-B2 | 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors | KMO, SNCA, AP1S1 | MMP12 1430/4885PKM 515/4885MAPT 496/4885 |
| US-20180170920-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | KMO, SNCA, AP1S1 | MMP12 1430/4885PKM 515/4885MAPT 496/4885 |
| US-20210380570-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MMP12 1433/4885PKM 4596/4885MAPT 3928/4885 |
| US-20190169178-A1 | METHODS | KMO, AMY2A, RNASE1 | MMP12 726/4885PKM 160/4885MAPT 3972/4885 |
| US-11932633-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | MMP12 1433/4885PKM 4596/4885MAPT 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.